Drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in patients with acute coronary syndrome (ACS) in terms of patient-oriented adverse events at 1 year, according to study results presented Saturday at the TCT Connect virtual conference.